China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced receiving clinical trial approvals from the National Medical Products Administration (NMPA) for two of its drugs, SHR-1905 and SHR7280. SHR-1905 will be assessed for the treatment of chronic sinusitis with nasal polyps, while SHR7280 is intended for controlled superovulation in assisted reproductive technology.
SHR-1905: A Monoclonal Antibody for Chronic Sinusitis with Nasal Polyps
SHR-1905 is a monoclonal antibody (mAb) that targets thymic stromal lymphopoietin (TSLP). This molecule has the potential to block the release of inflammatory cytokines, inhibit downstream inflammatory signal transduction, and ultimately improve the inflammatory state, controlling disease progression. Currently, no similar product is approved globally for the treatment of chronic sinusitis with nasal polyps. Hengrui Medicine has invested RMB53.64 million in the development of SHR-1905.
SHR7280: An Oral Small Molecule for Assisted Reproductive Technology
SHR7280 is an oral small molecule gonadotropin releasing hormone (GnRH) receptor antagonist. It can block the binding of endogenous GnRH to GnRH receptors, inhibit the synthesis and release of gonadotropins such as luteinizing hormone (LH), and prevent premature ovulation. As the first oral GnRH receptor antagonist for use in assisted reproduction, SHR7280 has required an investment of RMB105.78 million from the Chinese company for its development.-Fineline Info & Tech
